CBD is one of many natural cannabinoids derived from hemp and marijuana plants. CBD is non psychoactive, unlike another well know cannabinoid, THC. In 2018, the Farm Bill Act was passed legalizing hemp and CBD on a federal level. New farms, stores, and processors peppered the country within a few months. The CBD industry immediately rose to a billion-dollar trade in 2019, with projections of
Boston Hempire, a
Gadles and close friend,
Boston Hempire has core values of quality and transparency. Most of their products are organic, and all offerings are third party lab tested and fully insured with Cannabis Insurance Business. Each product in the Boston Hempire brand is grown and produced in
In early 2019, the company expanded with a full line of wellness products. Gadles states that all products have seen an uptick in sales since the start of COVID-19, especially Gummies and Soft Gels. Boston Hempire is not alone. Companies across the industry have seen a drastic increase in sales.
Claims cannot be made without approval from the FDA, but customers report a variety of benefits from CBD. Most statements include decreased pain (muscle and joint), anxiety, depression, stress, and better sleep. Because CBD is non-psychoactive and there are no known side-effects, many people are switching to CBD as a natural alternative to OTC and potentially addictive prescription drugs. The symptoms people are feeling caused by the pandemic align with the reported benefits of CBD, therefore supporting the large increase in sales.
Boston Hempire offers their entire selection of CBD products online at www.BostonHempire.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/boston-hempire-cbd-industry-sees-spike-in-sales-during-covid-19-pandemic-301072962.html
SOURCE Boston Hempire